Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07054894 ADME and bioavailability study in healthy volunteers
NCT07009353Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PF-07054894 (3 cohorts), sponsored by Pfizer. Primary endpoints: Cumulative recovery (%) of radioactivity in urine and feces (adjusted for vomitus, if any), expressed as a percent of total oral radioactive dose administered at 14 days and Metabolite identification/profiling in feces, plasma and urine at 14 days. Started Jun 2025; status: completed.
02
Drugs
PF-07054894
Beyond the preview
Go deeper on NCT07009353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07009353.